Esperion Therapeutics' (ESPR) Buy Rating Reiterated at HC Wainwright

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report)'s stock had its "buy" rating restated by investment analysts at HC Wainwright in a report released on Tuesday,Benzinga reports. They currently have a $16.00 price objective on the biopharmaceutical company's stock. HC Wainwright also issued estimates for Esperion Therapeutics' Q1 2025 earnings at ($0.16) EPS, Q2 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.15) EPS, Q4 2025 earnings at ($0.01) EPS, FY2025 earnings at ($0.43) EPS, FY2026 earnings at ($0.17) EPS, FY2027 earnings at $0.06 EPS and FY2028 earnings at $0.20 EPS.

Other analysts have also issued reports about the stock. StockNews.com lowered shares of Esperion Therapeutics from a "buy" rating to a "hold" rating in a research report on Friday, November 15th. JMP Securities reaffirmed a "market outperform" rating and issued a $4.00 target price (down from $7.00) on shares of Esperion Therapeutics in a report on Tuesday, February 11th. The Goldman Sachs Group started coverage on Esperion Therapeutics in a report on Wednesday, December 18th. They set a "neutral" rating and a $4.00 price target for the company. Needham & Company LLC restated a "buy" rating and issued a $6.00 price objective on shares of Esperion Therapeutics in a research note on Friday, December 13th. Finally, Cantor Fitzgerald assumed coverage on Esperion Therapeutics in a research report on Tuesday, December 17th. They issued an "overweight" rating and a $8.00 price objective for the company. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $6.75.

Remove Ads

Esperion Therapeutics Trading Up 6.3 %

Shares of NASDAQ:ESPR traded up $0.10 during trading on Tuesday, hitting $1.69. 3,260,581 shares of the company were exchanged, compared to its average volume of 4,053,618. Esperion Therapeutics has a fifty-two week low of $1.56 and a fifty-two week high of $3.94. The stock has a market cap of $332.99 million, a price-to-earnings ratio of -2.64 and a beta of 1.01. The firm has a fifty day moving average price of $1.96 and a two-hundred day moving average price of $2.08.

Hedge Funds Weigh In On Esperion Therapeutics

Large investors have recently made changes to their positions in the company. Mackenzie Financial Corp grew its holdings in Esperion Therapeutics by 116.1% in the 4th quarter. Mackenzie Financial Corp now owns 143,252 shares of the biopharmaceutical company's stock valued at $315,000 after buying an additional 76,965 shares in the last quarter. Two Sigma Advisers LP boosted its position in shares of Esperion Therapeutics by 0.4% in the fourth quarter. Two Sigma Advisers LP now owns 3,616,200 shares of the biopharmaceutical company's stock valued at $7,956,000 after acquiring an additional 16,100 shares during the period. Rafferty Asset Management LLC acquired a new position in shares of Esperion Therapeutics in the fourth quarter valued at about $82,000. ProShare Advisors LLC increased its position in Esperion Therapeutics by 75.2% during the fourth quarter. ProShare Advisors LLC now owns 62,549 shares of the biopharmaceutical company's stock worth $138,000 after acquiring an additional 26,843 shares during the period. Finally, Nuveen Asset Management LLC raised its stake in Esperion Therapeutics by 48.6% in the 4th quarter. Nuveen Asset Management LLC now owns 3,119,253 shares of the biopharmaceutical company's stock worth $6,862,000 after purchasing an additional 1,020,243 shares in the last quarter. Institutional investors own 47.39% of the company's stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.